15H-Cyclopenta(a)phenanthren-17-ol, acetate | 24684-52-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 15H-Cyclopenta(a)phenanthren-17-ol, acetate
• 英文别名: 15H-cyclopenta[a]phenanthren-17-yl acetate
• CAS: 24684-52-4
• 化学式: C₁₉H₁₄O₂
• 分子量: 274.3
• InChiKey: AHFVZMMCTZISHF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS<br/>[FR] COMPOSÉS CIBLANT DES RÉCEPTEURS HORMONAUX NUCLÉAIRES ANTICANCÉREUX
  申请人：NUVATION BIO INC

  公开号：WO2021097046A1

  公开（公告）日：2021-05-20

  The disclosure relates to anti-cancer compounds which are anti-cancer PARP inhibitors of formula Al, A2, A3 or A4 conjugated by a linker to a steroid, whereby the steroid targets the conjugate to the nucleus, as well as to methods for their preparation and use. (I)

  该披露涉及抗癌化合物，这些化合物是公式Al、A2、A3或A4的抗癌PARP抑制剂，通过连接剂与类固醇结合，从而使类固醇将该共轭物靶向到细胞核，以及其制备和使用的方法。
• LIBIDO-ENHANCING THERAPEUTIC AND USE
  申请人：Derivlan Bioscience, LLC

  公开号：EP3071207A1

  公开（公告）日：2016-09-28
• [EN] COMPOUNDS AND METHODS FOR TREATING NEOPLASIA<br/>[FR] COMPOSÉS ET PROCÉDÉS POUR TRAITEMENT DE LA NÉOPLASIE
  申请人：MEDEXIS S A

  公开号：WO2011029639A2

  公开（公告）日：2011-03-17

  The invention features compounds, pharmaceutical compositions and methods useful for the treatment of neoplasia. In particular embodiments, the compounds of the invention are useful for the treatment of multidrug resistant neoplasia.
• [EN] LIBIDO-ENHANCING THERAPEUTIC AND USE<br/>[FR] AGENT THÉRAPEUTIQUE AUGMENTANT LA LIBIDO ET UTILISATION
  申请人：DERIVLAN BIOSCIENCE LLC

  公开号：WO2015077407A1

  公开（公告）日：2015-05-28

  A composition for enhancing libido of a pharmaceutically effective amount of a libido-enhancing therapeutic of (5S,10R,13S,17S)-13-methyl-3-oxohexadecahydro-1H-cyclopenta[a]phenanthren-17yl acetate (Formula I), (3S,5S,10R,13S,17S)-3-hydroxy-13-methylhexadecahydro-1H-cyclopenta[a]phenanthren-17yl acetate (Formula II), (5S,10S,13S,17S)-17-hydroxy-13-methyltetradecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one (Formula III), isomers thereof, analogs thereof, or combinations thereof, and a pharmaceutically acceptable carrier. A method of enhancing libido, by administering the composition to an individual in need of an enhanced libido, and enhancing libido in the individual or animal which is male or female. A method of enhancing libido, by administering the composition of the present invention to an individual at an age when libido and sexual desire have naturally decreased, and enhancing libido in the individual. A composition for enhancing libido and arousal, including a pharmaceutically effective amount of a libido-enhancing therapeutic in combination with a sexual dysfunction therapeutic. A method of enhancing libido and arousal.